Article
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications.
Current hematologic malignancy reports - 8 Jan 2025
Faiz Mifra, Riedemann Merle, Jutzi Jonas S, Mullally Ann
Abstract excerpt
PURPOSE OF REVIEW: More than a decade following the discovery of Calreticulin (CALR) mutations as drivers of myeloproliferative neoplasms (MPN), advances in the understanding of CALR-mutant MPN continue to emerge. Here, we summarize recent advances in mehanistic understanding and in targeted therapies for CALR-mutant MPN. RECENT FINDINGS: Structural insights revealed that the mutant CALR-MPL complex is a tetramer...
Topics
- Calreticulin
- Humans
- Myeloproliferative Disorders
- Mutation
- Animals
- Molecular Targeted Therapy
- Signal Transduction
- Receptors, Thrombopoietin